{"id":"pl2200-aspirin-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PL2200 uses PLx Pharma's proprietary Phospholipid Delivery System (PDS) to coat aspirin with a protective phospholipid layer, which reduces direct contact with the gastric mucosa and decreases GI side effects. The formulation allows aspirin to be absorbed in the small intestine while maintaining its antiplatelet mechanism of action through irreversible cyclooxygenase (COX) inhibition.","oneSentence":"PL2200 is a modified-release aspirin formulation designed to reduce gastrointestinal irritation while maintaining antiplatelet efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:21.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal complications"},{"name":"Secondary prevention of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT01515657","phase":"PHASE3","title":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients","status":"COMPLETED","sponsor":"PLx Pharma","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT02008942","phase":"PHASE3","title":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients","status":"COMPLETED","sponsor":"PLx Pharma","startDate":"2014-01","conditions":"Diabetes Mellitus, Type 2","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PL2200 Aspirin Capsules","genericName":"PL2200 Aspirin Capsules","companyName":"PLx Pharma","companyId":"plx-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PL2200 is a modified-release aspirin formulation designed to reduce gastrointestinal irritation while maintaining antiplatelet efficacy. Used for Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal complications, Secondary prevention of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}